Holen Sie sich die Stockscreener-App
8.18
0.49%
0.04
Kyntra Bio Inc Aktie (KYNB) Neueste Nachrichten
Kyntra Bio, Inc. (NASDAQ: KYNB) Stock Price, News & Analysis - Kalkine
KIN stock holds steady as Kyntra Bio prepares new earnings update - AD HOC NEWS
Kyntra Bio to Present at H.C. Wainwright 28th Annual Global Investment Conference - quiverquant.com
A drug company's CEO will present in New York Sept. 15. Kyntra Bio will webcast it. - Stock Titan
KYNB Reiterated by HC Wainwright & Co. -- Price Target Maintained at $43 - GuruFocus
Oppenheimer reiterates Kyntra Bio stock rating on debt reduction - Investing.com
Kyntra Bio Streamlines Financing, Strengthens Balance Sheet - TipRanks
KYNB Looks 65.5% Overvalued on GF Value™ - GuruFocus
Kyntra Bio Cuts Royalty Payments to NQ Project Phoebus for Accelerated Upfront Payment - marketscreener.com
Kyntra Bio Amends Revenue Interest Deal With NQ Project Phoebus, Cuts Cap to $65M, Pays $42.6M - TradingView
Kyntra Bio Continues Balance Sheet Transformation with Material Reduction of Royalty Financing Obligation - marketscreener.com
Kyntra Bio (KYNB) Edges Higher to $8.02, Up 0.25% as Stock Holds Between Key LevelsSupply Zone - dars.gov.et
Enterprise value to revenue forward of Kyntra Bio, Inc. – BX:KYNB - TradingView
Kyntra Bio (KYNB) Q2 2026 Earnings Call Transcript - AOL.com
Kyntra Bio, Inc.Common Stock (Nasdaq:KYNB) Stock Quote - FinancialContent
Kyntra Bio Inc (KYNB) (Q2 2026) Earnings Call Highlights: Advanc - GuruFocus
Kyntra Bio, Inc. 2026 Q2ResultsEarnings Call Presentation (NASDAQ:KYNB) 2026-08-16 - Seeking Alpha
symbol__ Stock Quote Price and Forecast - CNN
Kyntra Bio Confronts Nasdaq Listing Risk as Asset and Revenue Shortfall Threatens Global Select Status - TipRanks
Kyntra Bio Inc. (KYNB) Holds Above Key Support After Modest PullbackSector Neutral Pair - vinanet.vn
Armistice Capital (KYNB) discloses 400,000-share, 9.88% Kyntra Bio position - Stock Titan
Kyntra Bio Inc Q2 Net Income From Cont Ops US - moomoo.com
KYNB Looks 28.4% Overvalued on GF Value™ - GuruFocus
Kyntra Bio: Q2 Earnings Snapshot - aol.com
Kyntra Bio Q2 adj. EPS $(4.68) misses $(3.18) estimate - scanx.trade
Kyntra Bio Q2 2026 slides: dual catalysts expected, cash into 2028 - Investing.com
Kyntra Bio Q2 2026 slides: prostate cancer, MDS programs eye Q4 catalysts - Investing.com
Earnings call transcript: Kyntra Bio rises as pipeline updates offset weak Q2 2026 sales - Investing.com
Kyntra Bio Q2 2026 Earnings Call: Complete Transcript - Benzinga
KYNB: Q2 2026 marked clinical progress and a return to profitability, with cash runway into 2028 - TradingView
Kyntra Bio (KYNB) Reports Q2 Loss, Lags Revenue Estimates - Yahoo Finance
Kyntra Bio, Inc. reports results for the quarter ended June 30Earnings Summary - TradingView
KYNTRA BIO ($KYNB) Releases Q2 2026 Earnings - Quiver Quantitative
Is Kyntra Bio Inc (KYNB) Facing Challenges After Q2 Earnings Mis - GuruFocus
Kyntra Bio (Nasdaq: KYNB) turns Q2 profit as deconsolidation gain offsets cash burn - Stock Titan
Kyntra Bio, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026 - marketscreener.com
Kyntra Bio Targets Late-2026 Milestones for Cancer and Anemia Drugs - Stock Titan
Kyntra Bio Reports Second Quarter 2026 Financial Results and Provides Business Update - marketscreener.com
KYNB Q1 2026 Earnings: EPS Miss Deepens as Losses Exceed ExpectationsRevenue Estimate Trend - vinanet.vn
Kyntra Bio, Inc. expected to post a loss of $3.18 a shareEarnings Preview - TradingView
Earnings Preview: Kyntra Bio to Report Financial Results Post-market on August 13 - 富途牛牛
KYNB Q1 2026 Earnings: Wider-than-Expected Loss Highlights Clinical-Stage Cash BurnGeographic Revenue Trends - vinanet.vn
KYNB Q2'26 Earnings: EPS estimate is (3.18) USD - TradingView
Kyntra Bio to Report Second Quarter 2026 Financial Results - GlobeNewswire
Kyntra Bio (KYNB) Expected to Beat Earnings Estimates: Should You Buy? - Yahoo Finance
KYNB Q2'26 Earnings: revenue estimate is 2.09M USD - TradingView
Kyntra Bio Inc. (KYNB) Edges Lower by 0.88% to $6.73 as Shares Consolidate Between Key Support and ResistanceCommon Gap - vinanet.vn
Kyntra Bio (KYNB) Holds Near $6.78 as Biotech Sentiment Remains CautiousHagopian Line - dars.gov.et
Kyntra Bio (KYNB) Holds Steady at $6.79 as Consolidation Builds Toward Key $7.13 TestLinear Regression - vinanet.vn
Kyntra Bio Inc. (KYNB) Holds Steady at $7.0 as Traders Eye Key LevelsFloat Adjusted Cap - dars.gov.et
Kyntra Bio Inc. (KYNB) Gains 1.56% as Stock Approaches Key ResistanceLinear Regression - dars.gov.et
Kyntra Bio, Inc. Revenue Breakdown – NASDAQ:KYNB - TradingView
Kyntra Bio, Inc. (KYNB) Q4 2024 Earnings ReportResults, Call & Slides - TipRanks
Kyntra Bio Inc. (KYNB) Q1 2026 Earnings: EPS Miss Widens as Pre-Revenue Biotech Faces R&D Cost PressureLong-Term Guidance - dars.gov.et
Kyntra Bio, Inc. (KYNB) Q1 2025 Earnings ReportResults, Call & Slides - TipRanks
Kyntra Bio, Inc. (KYNB) Q3 2025 Earnings ReportResults, Call & Slides - TipRanks
Kyntra Bio, Inc. (KYNB) Q2 2025 Earnings ReportResults, Call & Slides - TipRanks
Kyntra Bio, Inc. (KYNB) Q2 2024 Earnings ReportResults, Call & Slides - TipRanks
Kyntra Bio, Inc. (KYNB) Q1 2024 Earnings ReportResults, Call & Slides - TipRanks
Kyntra Bio, Inc. (KYNB) Q3 2024 Earnings ReportResults, Call & Slides - TipRanks
0.71%
2.84%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):